Abstract: The present invention provides a novel process for the preparation of 1-(2-{4-[(4-carbamoyl piperidin-1-yl)methyl]-N-methylbenzamido}ethyl) piperidin-4-yl N-({1, 1?-biphenyl}-2-yl) carbamate of formula (I).

Abstract: The present invention relates to a novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide of formula (I) The present invention also relates to the novel intermediate compounds of formula (V), formula (VII), and their processes for the preparation thereof. The present invention also relates to the use of compounds of formula (V), formula (VII) intermediate in the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1, 2, 4-oxadiazol-3-yl)-4, 6-dimethylpyridine-1-oxide of formula (I).

Abstract: The present invention relates to an improved process for the preparation of (4R)-1-[(2R, 4R, 5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one compound of formula-1 and its intermediate compounds. [Formula should be inserted here]. The present invention also relates to the process for the purification of (4R)-1-[(2R, 4R, 5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one compound of formula-1 to get pure compound of formula-1.

Abstract: The present invention relates to novel crystalline polymorphs of 1-[(3R)-3-[4-amino-3(4-phenoxy phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one represented by the following structural formula-1 and process for preparation thereof.

Abstract: The present invention relates to a novel process for the preparation of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4, 5, 6, 7-tetrahydropyrazolo[1,5-a] pyrimidine-3-carboxamide of formula-1 or its salts. The present invention also relates to novel process for the preparation of intermediate compound of Formula-7 and recovery of the intermediate compound of Formula-12, which is used in the preparation of compound of Formula-7. The compounds of formula-1 & formula-7 are represented by following structural formulae.

Abstract: The present invention relates to a pharmaceutical composition comprising N-(4-(6,7-dimethoxy quinolin-4-yloxy)phenyl)-N?-(4-fluoro phenyl) cyclopropane-1,1-dicarboxamide, (2S)-hydroxy butanedioate of formula-1 and a pharmaceutically acceptable carrier wherein the said pharmaceutical composition has a dimer impurity of formula-2 less than about 2.0% as measured by HPLC.

Abstract: The present invention relates to an improved process for the preparation of 4-({(1R)-2-[5-(2-fluoro-3-methoxy phenyl)-3-{[2-fluoro-6-(trifluoro methyl) phenyl] methyl}-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino) butanoic acid of formula (I) or its pharmaceutically acceptable salts.

Abstract: The present invention provides pure (1?R,6R,6aR,7R,13S,14S,16R)-5-(acetyloxy)-3?,4?,6,6a,7,13,14,16-octahydro-6?,8,14-trihydroxy-7?,9-dimethoxy-4,10,23-trimethyl spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7, 8]isoquino[3,2-b][3] benzazocine-20,1?(211)-isoquinolin]-19-one of formula (1) substantially free from one or more impurities selected from intermediate compound of formula (50), cyclic impurity of formula (A), deshydroxy impurity of formula (B) and hydroxy impurity of formula (C).

Abstract: The present invention relates to an improved process for the preparation of 3?,7?-dihydroxy6?-ethyl-5?-cholan-24-oic acid compound of formula-1, represented by the following structural formula: Formula-1 The present invention also relates to process for the preparation of ethylene diamine and tertiary butyl amine salts of 3?,7?-dihydroxy6?-ethyl-5?-cholan-24-oic acid which are useful in the preparation of pure 3?,7?-dihydroxy6?-ethyl-5?-cholan-24-oic acid.

Abstract: The present invention relates to process for the preparation of 2-(3,5-dichlorophenyl)-1,3- benzoxazole-6-carboxylic acid of formula (I), its pharmaceutically acceptable salts and polymorphs thereof which are used in the treatment of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.

Abstract: The present invention relates to novel crystalline forms of butanedioic acid 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide of formula-la and process for preparation thereof. The present invention also relates to a process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide. Further, the present application also relates to acid addition salts of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide and process for the preparation thereof.

Abstract: The present invention relates to novel crystalline polymorphs of sodium (4R,12aS)-9-{[(2,4-difluorophenyl) methyl] carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1?,2?:4,5] pyrazino[2,1-b] [1,3] oxazin-7-olate represented by the following structural formula-1a and process for their preparation. The present invention further relates to novel solvated forms of sodium (4R,12aS)-9-{[(2,4-difluoro phenyl) methyl] carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1?,2?:4,5] pyrazino[2,1-b][1,3] oxazin-7-olate compound of formula-1a and process for their preparation.

Abstract: The Present Invention relates to process for the preparation of 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one represented by the following structural formula-1.

Abstract: The present invention also relates to process for the preparation of N-(4-(6,7-dimethoxy quinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-malate compound of formula-1a and its polymorphs thereof, represented by the following structural:

Abstract: The present invention relates to novel polymorphs of 4-[3-chloro-4-(N?-cyclopropyl ureido) phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate represented by following structural formula-1a and process for preparation thereof. Further, the present invention relates to an improved process for the preparation of 4-[3-chloro-4-(N?-cyclopropylureido) phenoxy]-7-methoxyquinoline-6-carboxamide compound of formula-1 or its salts and its intermediates thereof.

Abstract: The present invention also relates to process for the preparation of N-(4-(6,7-dimethoxy quinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-malate compound of formula-1a and its polymorphs thereof, represented by the following structural:

Abstract: The present invention relates to solid state forms of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride compound of formula-1a and their processes for the preparation thereof and an improved process for the preparation of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride. The present inventors also provides an amorphous polymorph of the combination drug consisting of 2?-deoxy-5-(trifluoromethyl) uridine and 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione monohydrochloride and its process for the preparation.

Abstract: The present invention relates to novel polymorphs of 4-[3-chloro-4-(N?-cyclopropyl ureido) phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate represented by following structural formula-1a and process for preparation thereof. Further, the present invention relates to an improved process for the preparation of 4-[3-chloro-4-(N?-cyclopropylureido) phenoxy]-7-methoxyquinoline-6-carboxamide compound of formula-1 or its salts and its intermediates thereof.

Abstract: The present invention relates to an improved process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl] butanamide compound of formula-1, its intermediates, novel salt compounds of intermediates of the compound of formula-1. Further the use of novel salts in the preparation of the compound of formula-1. The present invention also relates to the novel process for the preparation of the compound of formula-1.

Abstract: Water soluble iron carbohydrate complex obtainable from an aqueous solution of iron (III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous oxone solution at a pH-value within the alkaline range, where, when one maltodextrin is present, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is present, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency anaemia conditions.